About N-acylneuraminate cytidylyltransferase
N-acylneuraminate cytidylyltransferase (CMAS) is a protein
from Homo sapiens identified by UniProt accession
Q8NFW8, 434 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | N-acylneuraminate cytidylyltransferase |
| UniProt accession | Q8NFW8 |
| Gene | CMAS |
| Organism | Homo sapiens |
| Length | 434 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- pancreatic adenocarcinoma · score 0.21
- neuroinflammatory disorder · score 0.15
- Benign familial chorea · score 0.05
- triple-negative breast cancer · score 0.04
- body height · score 0.03
- cancer · score 0.03
- neoplasm · score 0.02
- breast cancer · score 0.01
- infection · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NFW8-F1 | alphafold | PREDICTED | 87.73 | — |
Amino-acid sequence (434 residues)
MDSVEKGAAT SVSNPRGRPS RGRPPKLQRN SRGGQGRGVE KPPHLAALIL ARGGSKGIPL KNIKHLAGVP LIGWVLRAAL DSGAFQSVWV STDHDEIENV AKQFGAQVHR RSSEVSKDSS TSLDAIIEFL NYHNEVDIVG NIQATSPCLH PTDLQKVAEM IREEGYDSVF SVVRRHQFRW SEIQKGVREV TEPLNLNPAK RPRRQDWDGE LYENGSFYFA KRHLIEMGYL QGGKMAYYEM RAEHSVDIDV DIDWPIAEQR VLRYGYFGKE KLKEIKLLVC NIDGCLTNGH IYVSGDQKEI ISYDVKDAIG ISLLKKSGIE VRLISERACS KQTLSSLKLD CKMEVSVSDK LAVVDEWRKE MGLCWKEVAY LGNEVSDEEC LKRVGLSGAP ADACSTAQKA VGYICKCNGG RGAIREFAEH ICLLMEKVNN SCQK
Explore N-acylneuraminate cytidylyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets